Skip to main content
SpringerLink
Log in

Alternatives to Warfarin for Thromboembolism Prophylaxis in Nonrheumatic Atrial Fibrillation

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Decision-making regarding thromboembolism prophylaxis in atrial fibrillation remains a major clinical challenge. While evidence of the beneficial effect of anticoagulation for patients participating in clinical trials is well established, only half of eligible individuals in the general population are currently treated with warfarin. Using an evidence-based approach, this review covers major therapeutic approaches in practice toady and many of those expected to be released in the near future. Pharmacologic agents evaluated include warfarin, aspirin, other antiplatelets agents, direct thrombin inhibitors and antiarrhythmic drugs. Nonpharmacologic treatments reviewed include surgical and catheter ablation, pacing, left atrial appendage ligation and occlusion methods, and atrial defibrillators.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Domanski MJ. The epidemiology of atrial fibrillation. Coron Artery Dis 1995;6:95-100.

    Google Scholar 

  2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982;306:1018-1022.

    Google Scholar 

  3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.

    Google Scholar 

  4. Vidaillet H, Granada JF, Chyou PH, Maassen K, Ortiz M, Pulido JN, Sharma P, Smith PN, Hayes J. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002;113:365-370.

    Google Scholar 

  5. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study. Neurology 1978;28:973-977.

    Google Scholar 

  6. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: A risk profile from the Framingham Study. Stroke 1991;22:312-318.

    Google Scholar 

  7. Norris JW, Froggatt GM, Hachinski VC. Cardiac arrhythmias in acute stroke. Stroke 1978;9:392-396.

    Google Scholar 

  8. Nishide M, Irino T, Gotoh M, Naka M, Tsuji K. Cardiac abnormalities in ischemic cerebrovascular disease studied by two-dimensional echocardiography. Stroke 1983;14:541-545.

    Google Scholar 

  9. Lowe GD, Jaap AJ, Forbes CD. Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet 1983;1:784-786.

    Google Scholar 

  10. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-1764.

    Google Scholar 

  11. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999;131:492-501.

    Google Scholar 

  12. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-1953.

    Google Scholar 

  13. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406-1412.

    Google Scholar 

  14. Carroll K, Majeed A. Comorbidity associated with atrial fibrillation: A general practice-based study. Br J Gen Pract 2001;51:884-886, 889-891.

    Google Scholar 

  15. Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 2000;85:568-572.

    Google Scholar 

  16. Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-2389.

    Google Scholar 

  17. Albers GW, Yim JM, Belew KM, Bittar N, Hattemer CR, Phillips BG, Kemp S, Hall EA, Morton DJ, Vlasses PH. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996;156:2311-2316.

    Google Scholar 

  18. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med 2001;161:1443-1447.

    Google Scholar 

  19. Evans A, Davis S, Kilpatrick C, Gerraty R, Campbell D, Greenberg P. The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. J Clin Neurosci 2002;9:268-272.

    Google Scholar 

  20. Kelly AM, Kerr D, Hew R. Prevention of stroke in chronic and recurrent atrial fibrillation: Role of the emergency department in identification of ”at-risk” patients.Aust Health Rev 2001;24:61-65.

    Google Scholar 

  21. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, de Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: Executive summary a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines and policy conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American society of pacing and electrophysiology. Circulation 2001;104:2118-2150.

    Google Scholar 

  22. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. The atrial fibrillation followup investigation of rhythm management (AFFIRM) investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.

    Google Scholar 

  23. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators. Neurology 1993;43:32-36.

    Google Scholar 

  24. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Peterson P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002;288:2441-2448.

    Google Scholar 

  25. Kamath S, Blann AD, Chin BS, Lip GY. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. JAmColl Cardiol 2002;40:484-490.

    Google Scholar 

  26. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-1339.

  27. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.

    Google Scholar 

  28. Leebeek FW, Boersma E, Cannon CP, van de Werf FJ, Simoons ML. Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: Why were the results so unfavourable. Eur Heart J 2002;23:444-457.

    Google Scholar 

  29. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, Cataldo G, Milanesi G, Lavezzari M, Pamparana F, Coccheri S. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997;28:1015-1021.

    Google Scholar 

  30. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.

    Google Scholar 

  31. Sivenius J, Cunha L, Diener HC, Forbes C, Laakso M, Lowenthal A, Smets P, Riekkinen P Sr. Second European Stroke Prevention Study: Antiplatelet therapy is effective regardless of age. ESPS2Working Group. Acta Neurol Scand 1999;99:54-60.

    Google Scholar 

  32. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997;349:1569-1581.

    Google Scholar 

  33. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: A double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000;355:1205-1210.

    Google Scholar 

  34. Harenberg J, Weuster B, Pfitzer M, Dempfle CE, Stehle G, Kubler W, Schlierf G. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost 1993;19(Suppl 1):116-121.

    Google Scholar 

  35. Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, Bass EB. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane Review ). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.

    Google Scholar 

  36. Stellbrink C, Hanrath P, Nixdorff U, Hofmann T, Lehmacher W, Kuhle K, Fetsch T, Grewe R, Schmidt-Lucke JA, Anticoagulation in Cardioversion using Enoxaparin Study Group. Low molecular weight heparin for prevention of thromboembolic complications in cardioversion-rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin). Z Kardiol 2002;91:249-254.

    Google Scholar 

  37. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999;353:429-438.

    Google Scholar 

  38. Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kalebo P, Fager G, Gustafsson D. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002;87:231-237.

    Google Scholar 

  39. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW Jr. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002;137:648-655.

    Google Scholar 

  40. Maria Eriksson-Lepkowska, Anneli Thuresson, Susanne Johansson, Marita Larsson, Lars Frison, Anders Bylock, Ulf G. Eriksson The effect of the oral direct thrombin inhibitor ximelagatran on the pharmacokinetics of P450-metabolized drugs, in Healthy Male Volunteers [abstract]. Blood 2001;98:3987a.

    Google Scholar 

  41. Palle Petersen, on Behalf of the SPORTIF II and IV Investigators A Long-Term Follow-Up of Ximelagatran as an Oral Anticoagulant for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation [abstract]. Blood 2001;98: 2953a.

    Google Scholar 

  42. Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg 1999; 118: 833-840

    Google Scholar 

  43. Deneke T, Khargi K, Grewe PH, Laczkovics A, von Dryander S, Lawo T, Muller KM, Lemke B. Efficacy of an additional MAZE procedure using cooled-tip radiofrequency ablation in patients with chronic atrial fibrillation and mitral valve disease. A randomized, prospective trial. Eur Heart J 2002;23(7):558-566.

    Google Scholar 

  44. Bando K, Kobayashi J, Kosakai Y, Hirata M, Sasako Y, Nakatani S, Yagihara T, Kitamura S. Impact of Cox maze procedure on outcome in patients with atrial fibrillation and mitral valve disease. J Thorac Cardiovasc Surg 2002;124:575-583.

    Google Scholar 

  45. Raanani E, Albage A, David TE, Yau TM, Armstrong S. The efficacy of the Cox/maze procedure combined with mitral valve surgery: A matched control study. Eur J Cardiothorac Surg 2001;19:438-442.

    Google Scholar 

  46. Cox JL, Ad N. New surgical and catheter-based modifications of the Maze procedure. Semin Thorac Cardiovasc Surg 2000;12:68-73.

    Google Scholar 

  47. Gaita F, Riccardi R, Gallotti R. Surgical Approaches to Atrial Fibrillation. Card Electrophysiol Rev 2002;6:401-405.

    Google Scholar 

  48. Haissaguerre M, Gencel L, Fischer B, Le Metayer Ph, Poquet F, Marcus FI, Clementy J. Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994;5:1045-1052.

    Google Scholar 

  49. Jais P, Haissaguerre M, Shah DC, Chouairi S, Gencel L, Hocini M, Clementy J. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997;95:572-576.

    Google Scholar 

  50. Connolly SJ, Kerr CP, Gent M, Roberts RS, Yusuf S, Gillis AM, Sami MH, Talajic M, Tang ASL, Klein GJ, Lau C, Newman DM for The Canadian Trial of Physiologic Pacing Investigators. Effects of Physiologic Pacing versus Ventricular Pacing on the Risk of Stroke and Death Due to Cardiovascular Causes. N Engl J Med 2000;342:1385-1391.

    Google Scholar 

  51. Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, Marinchak RA, Flaker G, Schron E, Orav EJ, Hellkamp AS, Greer S, McAnulty J, Ellenbogen K, Ehlert F, Freedman RA, Estes NA 3rd, Greenspon A, Goldman L. Mode Selection Trial in Sinus-Node Dysfunction. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 2002;346:1854-1862.

    Google Scholar 

  52. Saksena S, Prakash A, Ziegler P, Hummel JD, Friedman P, Plumb VJ, WyseDG, Johnson E, Fitts S, Mehra R:DAPPAF Investigators. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. J Am Coll Cardiol 2002;40:1140-1150.

    Google Scholar 

  53. Mirza I, James S, Holt P. Biatrial pacing for paroxysmal atrial fibrillation: A randomized prospective study into the suppression of paroxysmal atrial fibrillation using biatrial pacing. J AmColl Cardiol 2002;40:457-463.

    Google Scholar 

  54. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755-759.

    Google Scholar 

  55. Sievert H, Lesh MD, Trepels T, Omran H, Bartorelli A, Della Bella P, Nakai T, Reisman M, DiMario C, Block P, Kramer P, Fleschenberg D, Krumsdorf U, Scherer D. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: Early clinical experience. Circulation 2002;105:1887-1889.

    Google Scholar 

  56. Crystal E, Lamy A, Connolly SJ, Kleine P, Hohnloser SH, Semelhago L, Abouzhar L, Cybulsky I, Shragge B, Teoh K, Lonn E, Sawchuk C, Oezaslan F. Left Atrial Appendage Occlusion Study (LAAOS): A randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. Am Heart J 2003;145:174-178.

    Google Scholar 

  57. Gold MR, Sulke N, Schwartzman DS, Mehra R, Euler DE: Worldwide Jewel AF-Only Investigators. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol 2001;12:1247-1253.

    Google Scholar 

  58. Ozcan C, Jahangir A, Friedman PA, Hayes DL, Munger TM, Rea RF, Lloyd MA, Packer DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK. Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol 2002;40:105-110.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Marshfield Clinic and St. Joseph's Hospital, Marshfield, Wisconsin, USA

    Ramin Artang & Humberto Vidaillet

Authors
  1. Ramin Artang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Humberto Vidaillet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Humberto Vidaillet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Artang, R., Vidaillet, H. Alternatives to Warfarin for Thromboembolism Prophylaxis in Nonrheumatic Atrial Fibrillation. J Interv Card Electrophysiol 10 (Suppl 1), 33–44 (2004). https://doi.org/10.1023/B:JICE.0000011344.01006.a1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:JICE.0000011344.01006.a1

Search

Navigation